Search

Your search keyword '"Witte, T."' showing total 2,661 results

Search Constraints

Start Over You searched for: Author "Witte, T." Remove constraint Author: "Witte, T."
2,661 results on '"Witte, T."'

Search Results

301. Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone to treat multiple myeloma patients progressing or relapsing after autologous transplantation: the MMVAR trial, a study from the myeloma subcommittee of the Chronic Leukemia Working Party of the EBMT

308. The Effect of Training on Stride Duration in a Cohort of Two-Year-Old and Three-Year-Old Thoroughbred Racehorses

309. ABRA – Fallvorstellung einer seltenen zerebralen Vaskulitis

310. Nail Psoriasis: The ignored disorder in Pso and PsA – Can ultrasonic and capillaroscopy findings in nail psoriasis patients accelerate diagnostic and effectice treatment?

311. Adsorbate induced manipulation of 1D atomic nanowires: Soliton mediated degradation of long-range order in the Si(553)-Au system

312. IDENTIFICATION OF FOUR NEW SHARED SUSCEPTIBILITY GENES IN SYSTEMIC SCLEROSIS AND CROHN¿S DISEASE THROUGH A CROSS-DISEASE META-GWAS

313. A CROSS-DISEASE META-GWAS IDENTIFIES IRF1, STAT3 AND ZBTB9-BAK1 AS NEW SHARED SUSCEPTIBILITY LOCI IN SYSTEMIC SCLEROSIS AND CROHN¿S DISEASE

321. Opposed independent effects and epistasis in the complex association of IRF5 to SLE

332. Intensive Chemotherapy Followed by Stem Cell Transplantation for the Treatment of Myelodysplastic Syndromes

334. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group

336. Gemtuzumab ozogamicin (Mylotargs®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups

342. Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF)

343. Abstract

349. The impact of post-remission therapy on outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy with or without stem cell transplantation in a joint study

Catalog

Books, media, physical & digital resources